二氮嗪胆碱缓释片治疗Prader-Willi综合征患者:一项双盲、安慰剂对照试验
DESTINY PWS是一项13周、随机、双盲、安慰剂对照的3期试验,纳入127例4岁及以上伴贪食的Prader-Willi综合征患者,按2:1随机分配至二氮嗪胆碱缓释片(DCCR)组或安慰剂组。DCCR未显著改善贪食(HQ-CT最小二乘均值[SE] -5.94 [0.879] vs -4.27 [1.145];P = .198),但在基线严重贪食患者中显著改善(-9.67 [1.429] vs -4.26 [1.896];P = .012),且3项次要终点中2项改善(CGI-I;P = .029;脂肪质量;P = .023)。
要点
- DCCR未显著改善总体贪食,但在基线严重贪食患者中显著改善。
- DCCR组CGI-I和脂肪质量较安慰剂组显著改善。
- DCCR组83.3%和安慰剂组73.8%发生治疗中出现的不良事件,差异无统计学意义。
核心结论
- DCCR在主要分析中未显著改善贪食,但在基线严重贪食患者和COVID前分析中显著改善。
- DCCR治疗与体成分和临床医生报告结局的显著改善相关。
研究设计与样本
- DESTINY PWS为13周、随机、双盲、安慰剂对照的3期试验,纳入127例4岁及以上伴贪食的Prader-Willi综合征患者,按2:1随机分配至DCCR组或安慰剂组。
主要发现
- 主要终点HQ-CT最小二乘均值[SE]:DCCR组-5.94 [0.879] vs 安慰剂组-4.27 [1.145];P = .198。
- 基线严重贪食患者HQ-CT最小二乘均值[SE]:DCCR组-9.67 [1.429] vs 安慰剂组-4.26 [1.896];P = .012。
- 3项次要终点中2项改善:CGI-I(P = .029)和脂肪质量(P = .023)。
- COVID前分析中,主要终点HQ-CT(P = .037)和所有次要终点均改善:CGI-I(P = .015)、照护者总体印象变化(P = .031)、脂肪质量(P = .003)。
- DCCR组83.3% vs 安慰剂组73.8%发生治疗中出现的不良事件,差异无统计学意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Prader-Willi syndrome (PWS) is a rare neurobehavioral-metabolic disease caused by the lack of paternally expressed genes in the chromosome 15q11-q13 region, characterized by hypotonia, neurocognitive problems, behavioral difficulties, endocrinopathies, and hyperphagia resulting in severe obesity if not controlled. OBJECTIVE: The primary end point was change from baseline in hyperphagia using the Hyperphagia Questionnaire for Clinical Trials (HQ-CT). Other end points included Global Impression Scores, and changes in body composition, behaviors, and hormones. METHODS: In DESTINY PWS, a 13-week, randomized, double-blind, placebo-controlled, phase 3 trial, 127 participants with PWS aged 4 years and older with hyperphagia were randomly assigned 2:1 to diazoxide choline extended-release tablet (DCCR) or placebo. RESULTS: DCCR did not significantly improve hyperphagia (HQ-CT least-square mean (LSmean) [SE] -5.94 [0.879] vs -4.27 [1.145]; P = .198), but did so in participants with severe hyperphagia (LSmean [SE] -9.67 [1.429] vs -4.26 [1.896]; P = .012). Two of 3 secondary end points were improved (Clinical Global Impression of Improvement [CGI-I]; P = .029; fat mass; P = .023). In an analysis of results generated pre-COVID, the primary (HQ-CT; P = .037) and secondary end points were all improved (CGI-I; P = .015; Caregiver Global Impression of Change; P = .031; fat mass; P = .003). In general, DCCR was well tolerated with 83.3% in the DCCR group experiencing a treatment-emergent adverse event and 73.8% in the placebo group (not significant). CONCLUSION: DCCR did not significantly improve hyperphagia in the primary analysis but did in participants with severe baseline hyperphagia and in the pre-COVID analysis. DCCR treatment was associated with significant improvements in body composition and clinician-reported outcomes.
引用
- Miller JL, Gevers E, Bridges N, et al. Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial. J Clin Endocrinol Metab. 2023. PMID: 36639249. doi:10.1210/clinem/dgad014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。